Page 57 - Read Online

Table 1: Evaluation of AML patients with extramedullary infiltration
Age Cytogenetics Molecular CD markers Extramedullary Subtype Prognosis References
(years), sex test site
51, female 46XX WT1+ MPO+, CD3-, Genital area AML with Poor [42]
(50%)/45XX del CD20-, TdT- multi-
(5)(q13q33), -7, lineage
add (15)(q22), dysplasia
-18
16, female PML-RAR at CD13+(85%), Right humerus, APL [43]
(15;17) CD15+, CD33+, right proximal
CD117+, CD34±, femur and distal
HLA-DR- tibia
19, male 11q23 HLA-DR+, Pulmonary M5 [44]
CD4+, CD11c+,
(MLL-AF10) CD13+, CD15+,
rearrangement, CD33+, CD117+,
low-level CD56+, CD45±

FLT3
inhibition
42, female t (8;21)-RUNX1- FLT3-ITD MPO+, CD34+, Auditory canal M2 Second [45]
RUNX1T1 Ki67 (60-70%) morphologic
CR
29, female 47, XX, +8, t MLL-AF9 CD117+, CD33+, Left and right M4 CR [20]
(9;11) (p22; q23) fusion gene CD38+, CD15+, breast
CD64+, CD4+,
CD56+
28, female No overt MLL-AF9 CD117+, CD13+, Left breast M4 CR [20]
cytogenetic fusion gene CD33+, CD34+,
aberration was CD38+, MPO+,
shown HLA-DR+
12, female t (9;11)(p22;q23) MLL gene CD45+, CD33+, Intra-abdominal M5 CR [46]
rearrangement CD4+, and presacral

alpha-1-
antitrypsin+,
muramidase+
15, female HLA-DR+, Abdomen M5a Poor [47]
CD33+, CD15+,
CD4+, CD11c+,
CD11b+, CD9+,
CD7+, CD56+,
CD14+
3-month, normal female MLL gene CD45+, CD33+, Skin M5 CR [47]
female karyotype - rearrangement CD117+, CD4+,
t(9;11) (p22; q23) CD1a+
10, male 45, X,-Y, del (2) CD13+, CD34+, Appendix M2 CR [48]
(p21), t(8;21) CD33+, MPO+,
(q22;q22) HLA-DR+
38, female t(6;21) CD13+, CD33+, Gastric M4 Poor [33]
CD34+, CD15+,
CD117+, CD64+,
CD65+, MPO+,
CD56+
57, male 47, XY, +8, 11q23, CD4+, CD13+, Forearm and thigh M5a No relapse [33]
t(9;11) (p22; q23) tetrasomy 8 CD16+, CD33+, during
CD56+ and chemotherapy
HLA-DR+
69, female MPO+, CD43+ Eye M1 Poor [49]
47, male t(8;17), t(17;17) CD33+, CD34+, Pancreas M2 [50]
CD117+
1, male t(15:17) PML-RARA CD33+, CD65+, Mandible APL [51]
MPO+
13, female 47, XX, +21 and CD45+, CD117+, Cardiac M5 Poor [52]
46, del (x)(q22) CD34+, CD43+,
CD68+

Contd...

Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ Issue 2 ¦ February 29, 2016 ¦ 47